AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02579590 — intervention group
Intervention type: DRUG
Intervention: Cerazette pills (75 micrograms desogestrel)
Description: where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
Study NCT02570659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Video
Description: A 14 minutes intervention video explaining the mechanism of the injury from cross-professional point of view and physiotherapeutic advise
Study NCT04567381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Services
Description: In enhanced services, the provision of services go beyond just referring a patient and leaving them to follow-through on their own accord. ES varies based on resources, model of service delivery, philosophy, and role and responsibilities of team members. Enhanced services usually includes longer-term case management which can then facilitate the connection to clinical counseling, victim assistance, familial assistance, legal assistance, emergency financial funding, transportation for subsequent appointments related to a patient's medical condition, employment assistance, and assistance in educational program enrollment.
Study NCT04567381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
Study NCT02844452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.
Study NCT02844452 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders. In an ideal controlled study, subjects would not know whether they were getting true or sham acupuncture. We are going to use Park Sham Acupuncture, which is composed of sham acupuncture needle not penetrating the skin of subjects and Park sham acupuncture device attacted on the subject's skin in order to block the seeing whether the acupuncture needle penetrates skin or not.
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Negative Control
Description: Untreated area
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control
Description: High SPF Standard P3/SPF 15
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Yosemite Falls (Forte Day SPF upgrade) Variant A
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Yosemite Falls (Forte Day SPF upgrade) Variant B
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product C
Description: Yosemite Falls (Forte Day SPF upgrade) Variant C
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product D
Description: Yosemite Falls (Forte Day SPF upgrade) Variant D
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product E
Description: Yosemite Falls (Forte Day SPF upgrade) Variant E
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product F
Description: Yosemite Falls (Forte Day SPF upgrade) Variant F
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product G
Description: Yosemite Falls (Forte Day SPF upgrade) Variant G
Study NCT00802321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
Study NCT03056612 — intervention group
Intervention type: OTHER
Intervention: Observation protocol
Description: The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
Study NCT02792595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product H
Description: Yosemite Falls (Forte Day SPF upgrade) Variant H
Study NCT03457623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Innovative Supported
Description: addition of connected tools and stronger accompaniment to improve quality of life
Study NCT03441100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA202 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
Study NCT00977925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Pad
Description: Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
Study NCT03922282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gasless BABA
Description: BABA robotic-thyroidectomy that is using elevation of flap instead of using carbon dioxide.
Study NCT03922282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic BABA
Description: BABA robotic-thyroidectomy that is using carbon dioxide.
Study NCT02583412 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bexsero®
Description: Multicomponent meningococcal B vaccine
Study NCT00977925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
Study NCT00929409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
Study NCT00929409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets
Description: Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
Study NCT03020121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy/biopsy
Description: Colposcopy/biopsy will be performed on all subjects
Study NCT01897974 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Families complete survey to measure medication compliance.
Study NCT02796235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Venous Doppler ultrasound of the lower limbs
Description: Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
Study NCT02583412 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®
Description: Hepatitis A vaccine
Study NCT06253910 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients selection
Description: Patient selection were selected according to selected criteria.
Study NCT06253910 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recall visits
Description: Following the operations, periodontal measurements were measured at the baseline, third month, first and second years.
Study NCT01770821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement and/or physical training
Study NCT01770821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary supplement and/or physical training
Study NCT01324921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No breakfast/beverage only
Description: 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
Study NCT01324921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: 1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
Study NCT01324921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10004RF
Description: 1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
Study NCT02566499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Microwave Imaging
Description: A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
Study NCT00698685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
Study NCT00698685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
Study NCT00698685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
Study NCT01197313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Study NCT03441100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.
Study NCT02784106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
Study NCT02784106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951
Description: Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.
Study NCT02784106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951
Description: Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
Study NCT00203879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)
Description: draft
Study NCT00203879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
Description: MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
Study NCT00390312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Intranasal placebo
Study NCT00390312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Morphine 15 mg
Description: Intranasal Morphine 15 mg
Study NCT00390312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Oral Morphine 60 mg
Description: Immediate Release Oral Morphine 60 mg
Study NCT00390312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Intravenous morphine 7.5 mg
Study NCT00390312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal morphine 7.5 mg
Description: Intranasal morphine 7.5 mg
Study NCT04918004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene
Description: 1. One-to-one sleep hygiene training, the content of which was created by the researchers,~2. A brochure containing 10 lifestyle changes related to sleep hygiene
Study NCT04043897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550mg
Description: Rifaximin 550mg
Study NCT00452907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: oad, per os, 3 days of treatment
Study NCT00452907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate + Sulfadoxine-Pyrimethamine
Description: oad, per os
Study NCT00452907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arthemether + lumefantrine
Description: bid, per os. Duration of treatment: 3 days
Study NCT02110004 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablation procedure
Description: The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
Study NCT02110004 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Picasso NAV Catheter
Study NCT02594787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phosphorus
Study NCT02594787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05101512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires on quality of life after surgery
Description: Patient has to answer different questionnaire about quality of life, pain, functional scores
Study NCT01739257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Lecture
Study NCT01739257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dramatic Reading
Study NCT03820297 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 10 sessions of ASGI
Description: 10-session intervention will occur weekly for 45 minutes per session: psychoeducation about mood and anxiety disorders, focusing on identification of risk factors and biological theory to counter stigma; psychoeducation regarding 'therapeutic modules' (psychotropics and psychotherapy) to treat depression, with an emphasis on the importance of psychiatric treatment adherence, providing behavioral strategies for anticipated and experienced forms of mental illness related work, social, or family discrimination
Study NCT01546246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water colonoscopy
Description: Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
Study NCT01300442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEDS in COPD patients
Description: For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
Study NCT01300442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEDS in healthy patients
Description: For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
Study NCT00506805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: dose escalated, tablets every other day; undetermined duration until disease progression
Study NCT03242512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection
Study NCT00504075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex, intravenous immunoglobulin
Description: Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
Study NCT01124968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eConsulta
Description: It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
Study NCT04517708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months
Study NCT01821768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Biopsy
Study NCT03993808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revision of congregate meal menus and recipes to align with parameters of DASH eating plan
Description: On a programmatic level, congregate meal menus and recipes have been adapted to align with DASH eating. The changes, which include the introduction of additional servings of fruits, vegetables, seeds, grains, replacement of simple or processed carbohydrates with healthier alternatives, introduction of more fish, reduction in added salt, and replacement of animal fats and butter with olive oil, will be phased-in in stages over 6 weeks, concurrent with the start up the study's educational programs addressing nutrition, BP, and medication adherence. The fully DASH-aligned menus will begin by week 7. The dietary intervention affects all seniors eating congregate meals at the center, not only those enrolled in this protocol to study the impact of DASH implementation.
Study NCT03993808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site blood pressure monitoring
Description: At baseline (Month 0), and at Months 1, 3, and 6 after the full implementation of the DASH aligned congregate meals, participants will have blood pressure measured by professionals, on-site at the senior center, following established standard procedures. They will receive verbal and written information about their blood pressure results, and encouragement to share the results with their providers.
Study NCT03993808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home self blood pressure monitoring
Description: Provision of personal Omron 10 home blood pressure monitoring device, training in proper use, and schedule for home self monitoring of BP over the course of the study.
Study NCT03993808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical adherence education
Description: One required educational session with the community pharmacist to learn about medication adherence strategies
Study NCT03993808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: One required educational session to review the elements of the DASH eating plan, how to overcome barriers to healthy eating, recipes, cooking demonstrations and materials for household members.
Study NCT02328079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)
Description: Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
Study NCT03496077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored and unflavored little cigars/cigarillos (LCCs)
Description: Flavored and unflavored LCCs that are currently available for purchase